JCI early table of contents for April 1, 2013

April 01, 2013

Promoting muscle regeneration in a mouse model of muscular dystrophy

Duchenne muscular dystrophy (DMD) is a degenerative skeletal muscle disease caused by mutations in the protein dystrophin. Dystrophin functions to protect muscle cells from injury and loss of functional dystrophin results in break down and loss of muscle cells. A cellular signal relay system, known as a MAP kinase cascade, regulates the function of muscle stem cells, serving as a source of the new cells that are required for muscle regeneration. In this issue of the Journal of Clinical Investigation, researchers led by Anton Bennett at Yale University identified the protein MKP-5 as a negative regulator of MAP kinase cascades in muscle stem cells. Loss of MKP-5 in a mouse model of DMD enhanced the development of new muscle cells (myogenesis) and helped prevent muscle degeneration. These results identify MKP-5 as an important suppressor of myogenesis and suggest that therapeutics that inhibit MKP-5 could be useful in the treatment of degenerative muscle diseases.

TITLE:
Improved regenerative myogenesis and muscular dystrophy in mice lacking MKP-5

AUTHOR CONTACT:
Anton Bennett
Yale University School of Medicine, New Haven, CT, USA
Phone: 203-737-2441; Fax: 203-737-2738; E-mail: anton.bennett@yale.edu

View this article at: http://www.jci.org/articles/view/64375?key=bbd026972477a9b98a24




Alternative fuel for your brain

Tight control of blood glucose levels is critical to mitigating the long-term complications of diabetes; however, the intensive insulin therapy required for this control is frequently accompanied by recurrent episodes of low blood sugar (hypoglycemia). Hypoglycemic episodes have been implicated in brain damage and cognitive impairment. Though the brain depends predominantly on glucose as an energy source, it can also use alternative fuels, such as lactate, to satisfy its energy requirements. In this issue of the Journal of Clinical Investigation, Raimund Herzog and colleagues at Yale University used magnetic resonance spectroscopy (MRS) to measure the concentrations and enrichment of different energy substrates and their metabolites in a rat model of recurrent hypoglycemia. They found that recurrent hypoglycemia enhances neuronal uptake of lactate which allows the brain to retain normal neural activity during hypoglycemia. These observations suggest that lactate supports neuronal function and indicate that supplementation of alternative fuels could protect the brain during hypoglycemia.

TITLE:
Lactate preserves neuronal metabolism and function following antecedent recurrent hypoglycemia

AUTHOR CONTACT:
Raimund I. Herzog
Yale School of Medicine, New Haven, CT, USA
Phone: 203-737-4773; E-mail: raimund.herzog@yale.edu

View this article at: http://www.jci.org/articles/view/65105?key=b71f996b96b91c84d096




ALSO IN THIS ISSUE

TITLE:
MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation

AUTHOR CONTACT:
Stanley Nattel
Montreal Heart Institute, Montreal, PQ, CAN
Phone: (514) 376-3330 ext. 3990; Fax: (514) 376-1355; E-mail: stanley.nattel@icm-mhi.org

View this article at: http://www.jci.org/articles/view/62185?key=ef2561a4a7949ec7f659

TITLE:
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

AUTHOR CONTACT:
Andrew Aplin
Thomas Jefferson University, Philadelphia, PA, USA
Phone: 215 503 7296; E-mail: Andrew.Aplin@KimmelCancerCenter.Org

View this article at: http://www.jci.org/articles/view/65780?key=f9536e266df3ab73b9f1

TITLE:
SLITRK6 mutations cause myopia and deafness in humans and mice

AUTHOR CONTACT:
Mustafa Tekin
University of Miami, Miami, FL, USA
Phone: 305-243-2381; Fax: 305-243-2703; E-mail: MTekin@med.miami.edu

View this article at: http://www.jci.org/articles/view/65853?key=b2bb9afa9e0cee02bd6b

TITLE:
Co-operativity of imprinted genes inactivated by acquired chromosome 20q deletions

AUTHOR CONTACT:
Anthony Green
University of Cambridge, Cambridge, , GBR
Phone: +44-1223-336829; E-mail: arg1000@cam.ac.uk

View this article at: http://www.jci.org/articles/view/66113?key=73dc8fe4bcb928ca86e4

TITLE:
The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases

AUTHOR CONTACT:
Arthur Weiss
Dept. Of Medicine, San Francisco, CA, USA
Phone: 415/476-8983; Fax: 415-502-5081; E-mail: aweiss@medicine.ucsf.edu

View this article at: http://www.jci.org/articles/view/66397?key=e400e2a8f6ccf1c7863b

TITLE:
Discovering naturally processed antigenic determinants that confer protective T-cell immunity

AUTHOR CONTACT:
Sebastian Joyce
Vanderbilt Univ. School of Medicine, Nashville, TN, USA
Phone: 615-322-1472; E-mail: Sebastian.Joyce@Vanderbilt.edu

View this article at: http://www.jci.org/articles/view/67388?key=c7801a36d65b917a2097
-end-


JCI Journals

Related Muscular Dystrophy Articles from Brightsurf:

Using CRISPR to find muscular dystrophy treatments
A study from Boston Children's Hospital used CRISPR-Cas9 to better understand facioscapulohumeral muscular dystrophy (FSHD) and explore potential treatments by systematically deleting every gene in the genome.

Duchenne muscular dystrophy diagnosis improved by simple accelerometers
Testing for Duchenne muscular dystrophy can require specialized equipment, invasive procedures and high expense, but measuring changes in muscle function and identifying compensatory walking gait could lead to earlier detection.

New therapy targets cause of adult-onset muscular dystrophy
The compound designed at Scripps Research, called Cugamycin, works by recognizing toxic RNA repeats and destroying the garbled gene transcript.

Gene therapy cassettes improved for muscular dystrophy
Experimental gene therapy cassettes for Duchenne muscular dystrophy have been modified to deliver better performance.

Discovery points to innovative new way to treat Duchenne muscular dystrophy
Researchers at The Ottawa Hospital and the University of Ottawa have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease.

Extracellular RNA in urine may provide useful biomarkers for muscular dystrophy
Massachusetts General Hospital researchers have found that extracellular RNA in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.

Tamoxifen and raloxifene slow down the progression of muscular dystrophy
Steroids are currently the only available treatment to reduce the repetitive cycles of inflammation and disease progression associated with functional deterioration in patients with muscular dystrophy (MD).

Designed proteins to treat muscular dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage.

Gene-editing alternative corrects Duchenne muscular dystrophy
Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

GW researcher finds genetic cause of new type of muscular dystrophy
George Washington University & St. George's University of London research, published in The American Journal of Human Genetics, outlines a newly discovered genetic mutation associated with short stature, muscle weakness, intellectual disability, and cataracts, leading researchers to believe this is a new type of congenital muscular dystrophy.

Read More: Muscular Dystrophy News and Muscular Dystrophy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.